27.1 C
Vientiane
Sunday, April 27, 2025
spot_img
Home Blog Page 326

JustMarkets Sets New Mobile Trading Standards After 10 months of Launch


HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 10 March 2025 – Since June 2024, JustMarkets, a globally recognized broker, has completely transformed its mobile app for traders to access markets with more ease and efficiency. Latest updates have positioned the app as a must-use platform for intuitive experience and trading on-the-go.

JustMarkets Sets New Mobile Trading Standards After 10 months of Launch
JustMarkets Sets New Mobile Trading Standards After 10 months of Launch

“Our priority is to give traders the best tools to succeed. With constant updates and new features on the horizon, our app will keep revamping to meet all the needs of modern traders,” – commented a JustMarkets representative.

Major Achievements and Milestones

Following the app update in 2024, JustMarkets faced notable growth and increased user engagement:

  • More than 200,000 new downloads across iOS and Android — a 55% increase compared to the previous period (August 1, 2024 – February 10, 2025).
  • 8 million sessions recorded — highlighting strong user engagement and demand for JustMarkets mobile trading solutions.
  • Expanded reach among iOS and Android users, with top download regions in Malaysia, South Africa, Jordan, Singapore, Nigeria, Iraq, Egypt and the UAE.


New Features Reshaping the Trading Experience

With a strong focus on user needs, the JustMarkets team refined both iOS and Android, guaranteeing a multifunctional, inclusive, and straightforward experience for every trader.

For Android Users:

  • New deposit bonus procedure to make bonus activation easier.
  • Symbol mini chart on trade screen that provides instant market insights.
  • Top movers & popular tab, highlighting trending assets.
  • New PIN code funnel that enhances account security and accessibility.

For iOS Users:

  • Top movers & popular tab — helping traders track key market trends.
  • Trading operations displayed on chart for a detailed representation of trades.
  • Changes for the new deposit bonus procedure to simplify its claim process.
  • New PIN code funnel that ensures effortless authentication.

User Feedback and Positive Reviews

The JustMarkets app transformations have been met with positive feedback from traders, and it continues to pour in. Here are a few recent comments from the Google Play and App Store review sections:

  • “It’s an amazing app!”
  • “This is the best broker I have ever experienced!”
  • “Been using JustMarkets since the beginning of 2024, and I’ve had no issues — deposits and withdrawals work smoothly, and the spreads are decent!”
  • “Very useful, transparent, and simple.”

What’s Next for JustMarkets Mobile Trading

The JustMarkets mobile trading app is available on Google Play and App Store. Over the past months, it underwent big improvements, making the app more user-friendly, technological, and feature-rich. It all started with the introduction of In-App Trading that allowed users to trade in real time without needing external platforms. Now, traders can seize opportunities right away, keep up with market movements from any place, and enjoy other astonishing benefits the team worked on for the last 8 months.

Looking forward, JustMarkets remains committed to further enhancements. Plans for 2025 include additional trading features, expanded payment options, and even better security measures.
Hashtag: #JustMarkets #MobileApp #JM





The issuer is solely responsible for the content of this announcement.

About JustMarkets

JustMarkets is a globally recognized multi-asset broker providing reliable and transparent trading services since 2012. The company has earned over 60 industry awards, highlighting its excellence in the financial sector. JustMarkets offers a diverse array of trading instruments, including forex, stocks, commodities, indices, metals, energies, and cryptocurrencies, serving clients in over 160 countries.

AIM Vaccine’s Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

HONG KONG, March 10, 2025 /PRNewswire/ — AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company’s research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration. This product is an upgraded version of the diploid rabies vaccine, featuring significantly high efficacy, marking a major iterative upgrade in the global rabies vaccine technology field. Animal trials have shown that the vaccine generates antibodies that provide a high level of protection, with efficacy significantly surpassing that of already marketed diploid rabies vaccines under the same dosage conditions.

This vaccine has successfully overcome the technical bottlenecks of traditional processes, which are characterized by low virus titer and low yield. Optimizations and innovations have been made in the purification process, resulting in significant improvements in product quality and safety. It can be administered using a five-injection method, a simplified four-injection method, or a 2-1-1 four-injection method, offering more flexibility and convenience.

Since February, AIM Vaccine has made several breakthrough advancements that highlight its innovative capabilities and global strategy. Its mRNA RSV (Respiratory Syncytial Virus) vaccine has received clinical approval in the U.S., and the company announced a comprehensive deployment of the DeepSeek large model, realizing a strategic upgrade to an “AI + Smart Vaccine Enterprise.”

In the context of major global investment banks raising target prices for Chinese assets, biotech stocks with high technological innovation content are expected to encounter significant opportunities. China Galaxy International Securities[1] believes that the pharmaceutical sector will undergo a recovery, and structural opportunities still exist. From the perspective of short-term and medium-to-long-term growth certainty, it is optimistic about the innovative pharmaceutical supply chain, international expansion, and leading companies in niche sectors.

Fosun International Securities[2] previously pointed out that AIM’s innovative products are driving a revaluation of its value. Considering AIM Vaccine’s strong R&D capabilities, technological leadership, and international market expansion potential, it has assigned a “Buy” rating with a target price of HKD 11.

Note 1: http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=GLH1848484L&catg=1&source=GLH

Note 2: http://www.aastocks.com/tc/stocks/news/glh-news/GLH1832345L/1

U.S. FDA approves Celltrion’s OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®

  • OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA
  • Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1]
  • The availability of the first omalizumab biosimilar will help increase access and potentially lower the healthcare cost for people with asthma and allergic diseases

JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ — Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2] 

“We are proud to achieve the approval of the first biosimilar to omalizumab in the U.S., which will help broaden access to this important medicine for patients with allergic and respiratory conditions, as well as for physicians, payers and providers,” said Hetal Patel, Vice President of Medical Affairs at Celltrion USA. “The interchangeability designation of OMLYCLO reinforces confidence among physicians and patients that there is no decrease in effectiveness or increase in safety risk associated with switching between OMLYCLO and the reference product.”

The FDA approval and designation of interchangeability are based on comprehensive clinical evidence, including results from a global Phase III clinical trial involving 619 adult patients with CSU up to Week 40. Patients were randomized to receive 300 mg or 150 mg of OMLYCLO or reference product every 4 weeks. From Week 12, patients who received OMLYCLO were continued on OMLYCLO, and patients who received 300mg of the reference product were re-randomized in a 1:1 ratio to switch to OMLYCLO or to continue reference product. From Week 24, patients were followed up until Week 40 without dosing. The result demonstrated the comparable efficacy and safety of OMLYCLO to reference product during both treatment and off-dose periods.[1]

An interchangeable biosimilar is a biosimilar that meets additional requirements outlined by the law that allows for the FDA to approve biosimilar and interchangeable biosimilar medications.[3]

“The approval of OMLYCLO could have a meaningful impact for the medical community and patients, offering a high quality and affordable treatment option, while reducing the burden of healthcare costs,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “With our integrated development, manufacturing, and commercialization platform, Celltrion remains committed to alleviating treatment costs and delivering life-changing medicines to support patients with allergic conditions in the U.S.”

About OMLYCLO® (omalizumab-igec)  

OMLYCLO® (omalizumab-igec) is the first U.S. Food and Drug Administration (FDA)-approved anti-IgE antibody biosimilar referencing XOLAIR® (omalizumab). OMLYCLO 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe is approved as interchangeable with reference product for all indications based on comprehensive data and clinical evidence confirming the therapeutic equivalence to XOLAIR.[1],[2] OMLYCLO was also approved by the European Commission (EC) in May 2024.

INDICATION

OMLYCLO® (omalizumab-igec) injection, is an anti-IgE antibody indicated for: 

  • Moderate to severe persistent asthma in adults and pediatric patients ≥6 years of age with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids
  • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients ≥18 years of age with inadequate response to nasal corticosteroids, as add-on maintenance treatment
  • IgE-mediated food allergy in adult and pediatric patients aged ≥1 year age for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance
  • Chronic spontaneous urticaria (CSU) in adults and adolescents ≥12 years of age who remain symptomatic despite H1 antihistamine treatment

Limitations of Use: Not indicated for: acute bronchospasm or status asthmaticus; emergency treatment of allergic reactions, including anaphylaxis; other forms of urticaria.

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of omalizumab products. Anaphylaxis has occurred as early as after the first dose of omalizumab products, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate OMLYCLO therapy in a healthcare setting and closely observe patients for an appropriate period of time after OMLYCLO administration.

Health care providers administering OMLYCLO should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of OMLYCLO should be based on criteria to mitigate risk from anaphylaxis.

Contraindications: Severe hypersensitivity reaction to OMLYCLO or any ingredient of OMLYCLO.

Anaphylaxis. Omalizumab products, including OMLYCLO, have been associated with anaphylaxis, reported in both clinical trials and postmarketing data. Patients with a history of anaphylaxis to foods, medications, or other causes face an increased risk. Initiate OMLYCLO only in a healthcare setting with anaphylaxis management capabilities. Patients should be monitored for an appropriate period post-administration, informed of symptoms, and instructed to seek immediate medical care if they occur.

Malignancy. Malignancies have been observed in clinical studies, with various cancer types reported. The long-term risk, especially in high-risk groups, is unknown.

Acute Asthma Symptoms and Deteriorating Disease. Omalizumab products have not been shown to alleviate asthma exacerbations acutely. Do not use OMLYCLO to treat acute bronchospasm or status asthmaticus.

Corticosteroid Reduction. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of OMLYCLO therapy for asthma or CRSwNP.

Eosinophilic Conditions. Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy, especially upon reduction of oral corticosteroids.

Fever, Arthralgia, and Rash. Stop OMLYCLO if a patient develops this constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy.

Parasitic (Helminth) Infection. Monitor patients at high risk of geohelminth infection while on OMLYCLO therapy.

Laboratory Tests. Omalizumab increases serum total IgE due to drug:IgE complexes. Do not use serum total IgE levels within one year of discontinuation to reassess dosing regimen, as they may not reflect steady-state free IgE.

Potential Medication Error Related to Emergency Treatment of Anaphylaxis. OMLYCLO should not be used for the emergency treatment of allergic reactions, including anaphylaxis. Instruct patients that OMLYCLO is for maintenance use to reduce allergic reactions, including anaphylaxis, while avoiding food allergens.

Most Common Adverse Reactions

  • Asthma: In patients ≥12 years, reported in ≥1%: arthralgia, general pain, leg pain, fatigue, dizziness, fracture, arm pain, pruritus, dermatitis, and earache. In pediatric patients (6 to <12 years), reported in ≥3%: nasopharyngitis, headache, pyrexia, upper abdominal pain, streptococcal pharyngitis, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.
  • CRSwNP: In ≥3% of adults: headache, injection site reactions, arthralgia, upper abdominal pain, and dizziness.
  • IgE-Mediated Food Allergy: In ≥3% of patients: injection site reactions and pyrexia.
  • CSU: In ≥2% of patients: nausea, nasopharyngitis, sinusitis, upper respiratory tract infections (viral and non-viral), arthralgia, headache, and cough.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has nine biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

OMLYCLO® is a registered trademark of CELLTRION, Inc.
XOLAIR® is a registered trademark of Novartis AG.

References

[1] Sarbjit Singh Saini et al., CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study. Available at: https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.16446?msockid=30d535870b30638b14c920090a18627c  [Last accessed March 2025]

[2] OMLYCLO U.S. prescribing information (2025)

[3] U.S. Food and Drug Administration (FDA). Available at: https://www.fda.gov/drugs/things-know-about/9-things-know-about-biosimilars-and-interchangeable-biosimilars [Last accessed March 2025]

US-OML-25-00001

For further information please contact: 
Andria Arena
aarena@jpa.com
+1 516-578-0057

Appian Unveils Latest Platform Release for Faster, More Powerful Data Fabric and AI Experience

SYDNEY, March 10, 2025 /PRNewswire/ — Appian (NASDAQ: APPN) today announced the latest version of the Appian Platform, which delivers improved scalability, speed, and performance for enterprise applications. Appian 25.1 introduces more document processing capacity with AI skills, centralised dashboards for monitoring process KPIs, and the ability to sync 10 million rows per record type in your data fabric.

Appian 25.1 allows you to process 75x more documents per hour. Extract and classify data from more pages, faster, with Appian AI skills.
Appian 25.1 allows you to process 75x more documents per hour. Extract and classify data from more pages, faster, with Appian AI skills.

With the platform’s improved AI architecture, organisations can now classify or extract data from hundreds of millions of pages per year with AI skills. Even applications handling high volumes of documents will experience fewer delays and bottlenecks with improved processing capabilities of up to 75 times more documents per hour.

“The results we experienced in the beta program exceeded our expectations,” said Rob Turverey, Director of Learning and Delivery at Groundswell. “We were hoping it would be 50% faster and were excited to see a 5x improvement! We believe these performance improvements will have a big impact on our customers.”

Data fabric architecture enhancements in 25.1 support greater scalability and performance throughout applications and in Process HQ. Updates include:

  • Performance improvements in Appian sites and applications: Participants of the data fabric enhancements beta program experienced 5–10 times faster performance for complex queries against record types with millions of rows – with some queries up to 40 times faster.
  • Improved data fabric scalability: Users can sync up to 10 million rows in each record type and store unstructured data in record fields to meet organisations’ growing data needs.
  • Comprehensive field-level security: New field-level security configurations offer greater control and compliance, supplementing existing record-level security settings across applications and Process HQ.

“We participated in the beta program for these new data fabric enhancements to evaluate the performance of our high-volume datasets with data fabric insights,” stated Michael D’Itri, Manager of Wireless DevOps Data & Tools at TELUS. “We were really happy with the performance and as a result, we are committed to investing further in the Appian data fabric capabilities this year.”

Appian 25.1 also enables users to add key performance indicators (KPIs) for processes to dashboards, allowing organisations to centralise information from process insights and data fabric insights. Users can drag and drop process KPIs onto the dashboard to view all relevant data in one place and link each KPI to a process for quick navigation.

The Appian Platform already makes it easy to build intuitive, information-dense interfaces. This release delivers component improvements that enhance UI experience, including editable grids, form layout formatting, and record components.

“Making AI valuable requires injecting it into business processes,” said Michael Beckley, CTO and Founder of Appian. “Appian 25.1 makes AI valuable by combining large language models with Appian’s class-leading autoscale process engine and Appian’s unique data fabric.”

Beckley continued, “Data fabrics are increasingly the preferred data plane in companies’ AI stacks, but most are optimised for read-only access and don’t scale well for writes beyond 2,000 rows per record. For Appian 25.1, Appian’s data fabric natively reads and writes 10 million rows per record, enabling AI to be reliably injected into mission-critical processes in all industries.”

For more information about the latest Appian Platform release, please visit appian.com/whats-new.

About Appian

Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world’s largest companies across industries. For more information, visit appian.com. [Nasdaq: APPN]

Follow Appian: LinkedIn, X (Twitter)

 

HKA WELCOMES FORENSIC ACCOUNTING EXPERT JACQUELINE WOODS TO HKA IN AUSTRALIA

SYDNEY, March 10, 2025 /PRNewswire/ — HKA, a leading global consultancy in risk mitigation and dispute resolution, is excited to announce that Jacqueline Woods has joined its rapidly expanding Forensic Accounting and Commercial Damages (FACD) team in Sydney, Australia. Jacqueline brings over 25 years of expertise in forensic accounting, particularly in valuations and loss quantification, bolstering HKA’s capability to address client needs in complex disputes.

Jaqueline Woods
Jaqueline Woods

Jacqueline’s career spans various sectors, where she has successfully resolved financial disputes as an independent expert in commercial litigation, family law and personal injury contexts. Jacqueline is also an accredited Expert Determiner, allowing her to resolve disputes as a single expert acting for both parties without the need for formal litigation.

Stuart Ells, Forensic Accounting and Commercial Damages Lead and Chief Growth and Operations Officer, International, stated, “I’m pleased to welcome Jacqueline as another senior member of our growing team of FACD Experts in Australia. Jacqueline’s extensive experience in forensic accounting, particularly her focus on valuations in shareholder disputes and family law, complements our existing service offerings and makes her an invaluable addition to the team in Australia and internationally. We are thrilled to welcome her aboard.”

Jacqueline’s educational credentials include a Master of Accounting and Economics from the University of Dundee, Scotland, and she is a Chartered Accountant and Expert Determiner. She has been involved in many significant engagements, such as expert determinations for shareholder agreements and post-acquisition disputes and financial investigations for transactions fraught with fraud risks. Her pragmatic approach and energetic demeanour will be instrumental in enhancing HKA’s service offerings.

“I am excited to join HKA during this period of growth and contribute to a team known for its excellence in forensic accounting,” said Jacqueline Woods. “I look forward to collaborating with my esteemed colleagues, leveraging our collective knowledge to provide tailored solutions that meet our clients’ diverse needs.”

Jacqueline’s inclusion in the FACD team follows the recent appointment of partners Andrew Ross, Anh Nguyen, John Temple-Cole, Sally Davitt, and Director Elizabeth Buchanan, who collectively enhance HKA’s footprint in the Asia Pacific market and internationally. With a combined wealth of knowledge and a robust approach to handling domestic and cross-border disputes, HKA continues to establish itself as a leader in the forensic accounting domain.

Jacqueline’s expertise further solidifies HKA’s position in providing comprehensive forensic accounting services across various jurisdictions.

For more information, visit www.hka.com 

Contact:
Peita Calvert
peitacalvert@hka.com

Aeroband Hits the Right Note at SXSW: The Best Smart Musical Instrument Brand Inspiring the Future of Music

Unleash the Rhythm of Inspiration at SXSW with Aeroband

AUSTIN, Texas, March 10, 2025 /PRNewswire/ — Aeroband, a leader in smart music technology, announces its participation at the 2025 South by Southwest (SXSW) Festival. At the event, Aeroband showcases its innovative products, including the Aeroband Guitar and PocketDrum, offering attendees an immersive music experience that celebrates creativity, innovation, and music culture.

Aeroband, known for transforming how people create and experience music, proudly presents its products at SXSW, a festival renowned for showcasing cutting-edge technologies and creative innovations. Aeroband Guitar and PocketDrum empower creators to make music anywhere, anytime. These products are perfect for both beginners and seasoned musicians, offering intuitive designs and powerful functionality that enhance the music-making experience.

Aeroband at SXSW Conference & Festivals 2025
Aeroband at SXSW Conference & Festivals 2025

Event Highlights

Interactive Booth – Austin Convention Center, Booth 209: Aeroband invites SXSW attendees to Booth 209 for an immersive, hands-on experience with the Aeroband Guitar and PocketDrum. Visitors will have the opportunity to explore the full capabilities of these innovative instruments, designed to make music creation more intuitive and accessible.

SXSW Instagram Engagement: As part of our commitment to fostering musical creativity, Aeroband is hosting a social media engagement activity at the booth. Attendees are encouraged to capture their experience with Aeroband Guitar or PocketDrum, share it on Instagram, and tag @aerobandofficial. Participants who complete this step will be entered into a giveaway, with a chance to win a PocketDrum. Winners will be randomly selected and notified after the event.

As a pioneer in smart musical instruments, Aeroband continues to revolutionize music technology with Aeroband Guitar and PocketDrum-designed for musicians of all levels. By integrating intuitive design, portability, and advanced digital capabilities, Aeroband empowers users to play, practice, and create music effortlessly, anytime, anywhere.

“At Aeroband, we believe technology should break barriers. Our goal is to make music more accessible, intuitive, and enjoyable for everyone—from beginners taking their first steps to seasoned musicians pushing creative boundaries,” said Frank, Founder & CEO of Aeroband. “We’re excited to showcase our innovations at SXSW, where creativity and technology come together.”

Smart Music Innovation at SXSW

Aeroband Guitar: Aeroband Guitar is an all-in-one, portable instrument that combines cutting-edge technology with an immersive musical experience. The silent practice feature lets you practice the guitar without disturbing others, while the multi-tone functionality, including piano tones, expands your sound options for a richer experience. For creators, the MIDI controller functionality allows seamless integration with digital music workstations, enabling endless music production and composition possibilities. Whether learning or creating, the Aeroband Guitar is a versatile tool that helps you express your musical creativity.

  • Multi-tone
  • MIDI Controller
  • Silent Practice

PocketDrum: PocketDrum is a revolutionary air drumming instrument that turns any surface into a responsive drum kit. Its quiet design ensures that musicians can practice without disturbing others, and its MIDI functionality connects to digital music platforms, allowing for endless creative possibilities. Whether at home or on the go, PocketDrum provides an immersive drumming experience that fits into any lifestyle.

  • Play Anytime, Anywhere
  • No Disturb
  • MIDI Controller

Both the Aeroband Guitar and PocketDrum are available for purchase directly from the Aeroband website or on Amazon, offering easy access to these innovative instruments for music enthusiasts everywhere. During SXSW, enjoy exclusive event discounts that unlock even greater value for your musical journey. Whether you’re just starting or already an experienced musician, these products are designed to unlock your full musical potential.

  • Aeroband Guitar: Available for $459.00
  • PocketDrum: Available for $179.00

For more information, please visit https://www.aeroband.net/pages/sxsw

About SXSW

South by Southwest (SXSW) is an annual festival in Austin, Texas, celebrating the convergence of technology, music, film, and culture. It has become a global platform for innovative creators, artists, and thinkers to share ideas and experiences. The 2025 SXSW Festival will take place from March 7th to March 15th.

About Aeroband

Aeroband is the world’s best smart musical instrument company, revolutionizing music technology with products like the Aeroband Guitar and PocketDrum. Designed for music lovers of all levels, Aeroband enables users to explore their musical creativity anytime, anywhere. Whether a beginner or a professional, Aeroband provides intuitive, innovative tools that empower you to express yourself through music.

Contact:
Lola Xu
Public Relations
Aeroband
Email: lola@aeroband.net
Website: https://www.aeroband.net/

Global Times: Up Close: President Xi joins national political advisors in education discussion

BEIJING, March 9, 2025 /PRNewswire/ — Chinese President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, visited national political advisors from the China Democratic League, the China Association for Promoting Democracy, and the sector of education, who are currently attending the third session of the 14th National Committee of the Chinese People’s Political Consultative Conference (CPPCC) in Beijing on Thursday. Xi attended their joint group meeting, and heard their comments and suggestions.

‘Education must not abandon fundamentals’

Artificial intelligence (AI) is empowering education. New tracks and opportunities have emerged, accompanied by new challenges and concerns.

Xu Kun, a member of the 14th National Committee of the CPPCC from Beijing University of Posts and Telecommunications, shared his insights from practice. “AI has become a key variable in accelerating the transformation from a large educational country to a strong educational country,” Xu said.

Xi showed keen interest in this topic: “With the digitalization of education, some issues need to be clarified.”

On one hand, with the rise of the Internet of Intelligence and AI, the tools and methods of education will change, as will the development of students’ capacities, requiring reforms that keep pace with the times. On the other hand, the enlightenment of students’ minds, the nurturing of their hearts and the development of basic cognitive and problem-solving skills must not be neglected. The fundamentals must still be maintained, Xi said.

Comparing with the past, he gave an example: “In the past, when shopping at a store, some people had to count change one by one at a time, which often indicated a lack of basic mathematical skills. After the advent of calculators, the demands on these basic skills shifted compared with the days of using an abacus. Even so, education must not abandon the fundamentals.”

As the saying goes, “To ensure a good outcome, one must establish a solid foundation; to achieve a good future, one must be meticulous from the start.” In today’s surging wave of digitalization, what are the “fundamentals” that education must not abandon?

The inheritance of the “red gene,” for instance.

Ma Jinglin, a member of the 14th National Committee of the CPPCC from Beijing No. 4 High School, spoke on the theme of cultural inheritance and cultural confidence. “Schools plant a seed in a person’s heart. Primary schools, middle schools and even kindergartens play a crucial role in a person’s life. We must start from children.” “We should effectively integrate the ‘small classroom’ of ideological and political education with the ‘big classroom’ of society,” Xi said.

This instruction reflects a steadfast resolve amid the changes of the times.

“Education must hold firm, cultivating patriotism from a young age,” said Xi earnestly. “Instilling ideals and firm beliefs from childhood ensures that, as they grow, the cause of socialism with Chinese characteristics will have reliable successors.”

Another example is reading.

Cultural prosperity relies on the spiritual nourishment brought by reading. “Fragmented reading” is also one of the “worries” that accompany digitalization.

In the digital age, with society moving at a fast pace, it’s not easy to sit down quietly and patiently to read a book. From the families with a culture of reading in the past to today’s advocacy for building a culture of reading on campuses and in society, the president expressed his deep hope: “A culture of reading is an atmosphere.”

Zheng Jiajian, another member of the 14th National Committee of the CPPCC from Fujian Normal University in East China’s Fujian Province, proposed “building a diverse and multidimensional reading ecosystem for children and adolescents.” “Digital reading should be combined with traditional reading to preserve our core and cultivation,” Xi affirmed.

This instruction highlights a strategy of harnessing technology for our benefit.

With an internet cable, a screen and a platform, quality educational resources transcend mountains and seas. In recent years, education has taken flight on digital wings, presenting a myriad of achievements. Implementing the national strategy for digital education has been incorporated into the Master Plan on Building China into a Leading Country in Education (2024-35). China’s ranking in the global digital education development index has risen to ninth place.

“To implement the national strategy for digital education and build a learning society, we must promote the emergence of talent at all levels and in all fields.” During his visit to the group, Xi engaged in in-depth exchanges with everyone on this topic.

In the face of opportunities brought by digital education, maintaining resolve while taking proactive steps aims to foster an atmosphere with the culture of books, and a wealth of talent, all for the future of the Chinese nation.

‘Education must plan ahead and act swiftly’

Education is a cornerstone of the country and the Party.

“Every family pays attention to education, and there are many hot topics in this area, indicating a strong educational atmosphere. It also reflects that our education still falls short of the people’s expectations in some respects.” Xi’s concerns unfolded from the issue of aligning talent cultivation with practical needs.

In the exchange of questions and answers, a metaphor stood out: “Turning a corner.”

After the speech by Zhang Yunkai, a member of the 14th National Committee of the CPPCC from the Traffic Vocational-Technical School of Hebei Province in North China, Xi inquired in detail about student employment rates and the recent progress of “order-based” classes in school-enterprise cooperation, discussing the changing dynamics of talent supply and demand, and the positioning of vocational schools.

“Talent follows a shifting supply-demand relationship, and education must plan ahead and act swiftly.” Xi’s words carried a sense of urgency: “This isn’t something that can be reoriented with a few words. It requires one or two ‘five-year plans’ to align properly. Many factors need to be considered in the process. If we don’t plan now, it’ll be too late when the time comes.”

“Vocational schools must adapt to real supply and demand needs, which involve structural adjustments in education. Structural adjustment is a systemic process, a vector change influenced by multiple factors. Education is both a matter of utmost importance and an extremely complex issue. It requires persistent effort over time, yet it is also an urgent priority.”

In the conversation, a comparison provided a sharp contrast: “Good schools are defined by great teachers, not just grand buildings.”

Cai Guangjie, a member of the 14th National Committee of the CPPCC and deputy director of the Department of Education of Southwest China’s Sichuan Province, noted that in recent years, as population distribution has shifted toward cities and the school-age population decreases in stages, new challenges have emerged, such as the coexistence of a surplus and shortage of school places and an imbalanced teacher workforce structure.

We must align with the needs of modernization, adapt to demographic changes, coordinate basic education, higher education, and vocational education, and balance government and societal investments to establish a more rational and efficient mechanism for allocating educational resources, Xi said.

How can there be a balance between quantity and quality? How can timing and effectiveness be coordinated in an orderly manner? “Some schools are built to be ‘grand and imposing,’ but good schools are defined by great teachers, not just grand buildings. We must focus on improving quality, pursuing connotative development, and addressing existing problems.”

Problems are the voice of the times. Educational challenges must be viewed from both sides, dialectically, and with a long-term perspective. “These are new issues brought by changes in progress. The process of solving problems is also the process of advancing development.”

“Our own educational journey has undergone earth-shaking changes!” Xi’s words have painted a grand picture of New China’s educational development history, unfolding like a scroll.

In times of poverty and scarcity, literacy classes were held to eradicate illiteracy. “Back then, it was a question of whether people could eat enough. The entire Chinese population tightened their belts, and education funding was stretched thin,” Xi recalled.

At the dawn of reform and opening-up, from collective fundraising for schools to the “Hope Project,” how many children’s dreams were ignited. “Back then, I helped raise funds to build a primary school in Liangjiahe village in Northwest China’s Shaanxi Province, and I was quite pleased. Later, why did it disappear? It was a good thing – schools were centralized in townships to improve education quality. That was another structural adjustment in education,” Xi said.

When he was a young man, Xi spent seven years in Liangjiahe, a poor village at the time in Shaanxi. After witnessing the hardship of people’s lives in the barren mountains, Xi resolved to become a public servant and do some good for the people.

Into the new century and the new era, schools rebuilt in disaster areas, deep in the mountains, and in ethnic regions… have collectively borne witness to the thriving progress of Chinese education.

Times have changed, and the world has transformed. Today, China has built the world’s largest education system, with its overall level of educational modernization entering the upper-middle ranks globally. The once-illiterate country has become an education powerhouse, now advancing toward a leading country in education, while the populous country has grown into a human resources giant.

The report to the 20th CPC National Congress dedicated a chapter to education, science and talent, sounding the clarion call to accelerate the building of a country with powerful education. Each journey brings new landscapes, where opportunities and challenges coexist. Deepening comprehensive education reform seeks to adapt to the changes of the times, anchoring the new journey of advancing the socialism with Chinese characteristics.

Xi’s remarks resounded through the venue. “In the new era and on the new journey, we must deeply grasp the demands of Chinese modernization on education, science, and talent, strengthen education’s supporting role in science and talent development, and further create a vibrant landscape where talents emerge in abundance, fully realize their potential, and put their abilities to optimal use.”

https://www.globaltimes.cn//page/202503/1329784.shtml

 

Fundamental Analysis in Trading: How Economic Indicators Shape Market Decisions – Insights from Octa Broker


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 9 March 2025 – In 2025, global markets are navigating a phase of economic uncertainty as potential inflationary pressures induced by trade tariffs, shifting central bank policy, and geopolitical risk shape trading conditions. Traders who integrate fundamental analysis into their strategies can navigate these uncertainties more effectively, positioning themselves ahead of major market movements. Kar Yong Ang, a financial market analyst at Octa Broker, explains how traders can leverage fundamental analysis to anticipate market shifts and capitalise on economic developments.

Octa

Basics of Fundamental Analysis
Fundamental analysis is a method of analysing how political and macroeconomic factors can affect the future price of an asset. Traders normally evaluate geopolitical events, economic releases, and industry trends. Both macroeconomic and microeconomic statistics, including GDP, employment data, and company profits, are employed in the analysis. For example, the German economic slowdown of 2024, driven by mounting energy prices and decreasing industrial output, led to a reduced 2025 growth forecast of just 0.3%, and this affected German equities and investor sentiment.

Government policies and central bank actions have a strong impact on market sentiment. For instance, in 2025, fresh U.S. tariffs on Chinese imports fuelled stagflation concerns, leading to a rise in gold prices while weakening risk-sensitive currencies.

‘Another recent example of how policies impact markets is when, in February 2025, President Trump put a 25% tariff on imports of steel and aluminum starting from March 12. The policy was to protect domestic industry but created a threat of rising inflation and slowing economy’, shares Kar Yong Ang. ‘The market response was quick. By the end of February, CME Midwest Domestic hot-rolled coil steel costs has increased by more than 30% since Mr. Trump entered his office. American business activity dropped considerably, with the S&P Global Flash U.S. Composite PMI Output Index dropping to 50.4 in February from 52.7 in January, its lowest level since 17 months ago. The fall was attributed to increasing tariffs and federal government expenditure reductions that made financial conditions tighten across industries’.

How Fundamental Analysis Differs from Technical Analysis
While technical analysis focuses on price charts and trends, fundamental analysis considers broader economic and corporate financial factors to predict an asset’s value. Blending both methods enhances decision-making. Those who rely only on technical analysis risk ignoring some external factors that may drive price increases or drops, regardless of indicator-based insights. What is more, conducting both technical and fundamental analyses allows you to identify more facts to support your trading assumption or spot emerging facts that contradict your trading hypothesis. This reduces the risk of implementing speedy, chaotic decisions.

Client-focused brokers tend to include fundamental and technical analysis capabilities in their trading platforms’ toolkits. For example, Octa broker’s proprietary platform, OctaTrader, features Space, a feed of expert-curated insights embedded into the app. Space offers relevant and timely trading ideas anchored in fundamental and technical analysis and allows traders to copy these ideas to their charts in a couple of clicks, enhancing decision-making and driving more informed, precision-based trading.

Key Economic Indicators Every Trader Should Track

  • Gross Domestic Product (GDP). A key measure of economic strength, GDP growth typically boosts investor confidence, leading to stock market gains and increased corporate investment. Conversely, a contracting GDP signals economic distress, often triggering market sell-offs, weaker consumer spending, and potential central bank interventions to stimulate growth. In 2024, the U.S. GDP grew by 2.8%, supporting stock market confidence.
  • Inflation Rates. Inflation is a key indicator which erodes purchasing power of a consumer and shapes monetary policy. Almost all central banks in the world set inflation targets, typically around 2%. Stable inflation is essential for long-term economic growth. To meet the target, central banks adjust their monetary policies. If inflation rises too quickly, the monetary policy is tightened: interest rates are raised to slow down spending and borrowing. Conversely, deflation often leads to reduced interest rates or stimulus packages.
  • Interest Rates. While central bank decisions on interest rates influence economic growth and exchange rates, investors’ expectations of the future rate changes have the greatest impact on financial markets. Traders watch closely for signals because differences in rate expectations between large economies are a key driver of currency value shifts.
  • Unemployment and Labour Market Data. Labour market health influences consumer spending and economic stability. Essentially, all major central banks focus on both inflation and employment. Strong labour markets are typically supportive of economic growth and can lead to monetary policy tightening if rising wage pressures raise inflation. The most watched indicator is U.S. Non-Farm Payrolls (NFP), which traditionally has the biggest immediate impact on markets. A higher-than-expected NFP can harden the dollar and improve rate hike expectations, while a weak report might lead to dovish central bank warnings and low bond yields.
  • Trade Balance and Current Account. A balance of trade—a country’s exports over its imports—has a direct impact on the currency value. When there is a trade surplus (exports outpacing imports), the country’s currency strengthens: foreign customers have to acquire the domestic currency to settle payments for products and services, pushing demand. A trade deficit (imports exceeding exports), on the other hand, weakens the domestic currency since more money is exported to buy foreign goods, increasing the supply of the local currency in foreign markets.

How Traders Use Economic Calendars
Economic calendars are essential resources for traders since they provide scheduled releases of important economic data, central bank statements, and geopolitical events.

Traders who follow the events can anticipate potential market fluctuation and prepare a potentially profitable trade or apply risk management. For example, set or adjust stop-loss, as well as close all the positions to hold out potential volatility. Itэs important to protect your funds, even if you strongly anticipate specific decisions on interest rate, inflation, and so on. From time to time, the market faces monetary policy surprises when a central bank takes an unexpected decision, urging market volatility: for example, ECB’s negative interest rates in 2014, Fed’s emergency rate cuts in 2020, or Bank of Canada’s rate hike pause in 2023.

Risk Management in Fundamental Analysis
Volatility is a natural сhallenge for any trader, especially during major economic events. Central bank decisions, inflation levels, and political tensions have a tendency to trigger aggressive price movements, which render risk management a core component of any strategy. Professional traders employ hedging instruments and prudent position sizing to contain potential losses in order to control these movements.

Geopolitical events are a great example of the impact of external forces on trading. The Russia-Ukraine war, for instance, disrupted energy supplies and increased oil prices, rewarding the traders who had anticipated these shortages in supply. Those who were closely monitoring geopolitical events and taking position adjustments were able to capitalise on such price fluctuations, validating the inclusion of geopolitical analysis in trading models. President elections are another event to watch. For instance, traders who followed the 2024 US elections could have prepared for market volatility by anticipating Trump’s tariffs and his more friendly stance on the crypto industry.

By tracking key economic indicators such as GDP growth, inflation, and interest rates, traders can make long-term forecasts and adjust their positions to take advantage. Coupling fundamental knowledge with technical analysis allows to make trading strategies stronger, enhancing the decision-making process. This approach also improves risk management as traders analyse more factors and can better identify potential price movements.

__

Disclaimer: Trading involves risks and may not be suitable for all investors. Use your expertise wisely and evaluate all associated risks before making an investment decision.

Hashtag: #Octa

The issuer is solely responsible for the content of this announcement.

Octa

is an international CFD broker that has been providing online trading services worldwide since 2011. It offers commission-free access to financial markets and various services used by clients from 180 countries who have opened more than 52 million trading accounts. To help its clients reach their investment goals, Octa offers free educational webinars, articles, and analytical tools.

The company is involved in a comprehensive network of charitable and humanitarian initiatives, including the improvement of educational infrastructure and short-notice relief projects supporting local communities.

In Southeast Asia, Octa received the ‘Best Trading Platform Malaysia 2024’ and the ‘Most Reliable Broker Asia 2023’ awards from Brands and Business Magazine and International Global Forex Awards, respectively.